Traders should monitor the sBLA submission for Ziihera in first-line GEA in 1Q 2026 and potential NCCN guideline inclusion as near-term catalysts. The Royalty Pharma financing de-risks the balance sheet and extends cash runway beyond 2028, supporting continued buybacks or strategic acquisitions. Upcoming data presentations at AACR in April 2026 could provide additional R&D momentum.
Price Chart
Executive Summary
Zymeworks reported strong 2025 financial results with 39% revenue growth to $106.0 million and a 34% reduction in net loss to $81.1 million. The company secured $250.0 million in non-dilutive financing from Royalty Pharma and is executing a $125.0 million share repurchase program, having already used $62.5 million. Key catalysts include the potential U.S. approval and 2026 launch of Ziihera in first-line HER2+ gastroesophageal cancer, which could trigger up to $440.0 million in milestone payments.
Key Financial Metrics
Key Facts
- Total revenue for 2025 was $106.0 million, up 39% from $76.3 million in 2024
- Net loss for 2025 was $81.1 million, a 34% improvement from $122.7 million in 2024
- Entered into $250.0 million non-recourse royalty-backed note financing with Royalty Pharma
- Utilized $62.5 million of a $125.0 million share repurchase program as of March 2, 2026
- Partner Jazz expects to submit sBLA for Ziihera in first-line HER2+ GEA in 1Q 2026 with potential U.S. launch in 2H 2026
- Eligible for up to $440.0 million in milestone payments from Jazz and BeOne for Ziihera approvals in GEA across U.S., Europe, Japan, and China
- Cash, cash equivalents, and marketable securities totaled $270.6 million as of December 31, 2025
- Guided for approximately $300.0 million in adjusted gross operating expenses (non-GAAP) over 2026–2028, with 2026 expenses ~20% lower than 2025
Financial Impact
Revenue increased by $29.7 million YoY; net loss reduced by $41.6 million; $250.0 million non-dilutive financing secured; $62.5 million returned to shareholders via buybacks
Risk Factors
- Regulatory delay or rejection of Ziihera sBLA in first-line GEA
- Failure to realize anticipated milestone payments from partners
- Clinical setbacks in wholly-owned pipeline programs (ZW191, ZW251, ZW209, ZW1528)
- Execution risk around cost discipline and operating expense reductions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247159 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $27.47 $27.50 | ▲ +0.11% | ▼ −0.87% | $25.15 (−8.45%) |
Jul 16, 2026 11w ago | Press Release | $24.19 $25.76 | ▼ −6.49% | ▼ −2.87% | $25.15 (−3.97%) |
Jun 29, 2026 13w ago | Press Release | $24.10 $22.86 | ▼ −5.15% | ▼ −4.87% | $25.15 (+4.36%) |
Jun 14, 2026 15w ago | Press Release | $23.26 $24.94 | ▲ +7.22% | ▲ +7.97% | $25.15 (+8.13%) |
May 15, 2026 19w ago | 3 | $24.43 $22.49 | ▼ −7.94% | ▼ −9.52% | $25.15 (+2.95%) |
Apr 21, 2026 23w ago | Press Release | $28.53 $24.40 | ▼ −14.48% | ▼ −17.64% | $25.15 (−11.85%) |
Apr 17, 2026 24w ago | Press Release | $27.80 $23.96 | ▼ −13.81% | ▼ −19.18% | $25.15 (−9.53%) |
Apr 16, 2026 24w ago | Press Release | $27.20 $24.57 | ▼ −9.67% | ▼ −15.48% | $25.15 (−7.54%) |
Apr 10, 2026 25w ago | 3 | $26.17 $24.03 | ▼ −8.18% | ▼ −15.91% | $25.15 (−3.90%) |
Mar 17, 2026 28w ago | Press Release | $23.45 $27.20 | ▲ +15.99% | ▲ +9.94% | $25.15 (+7.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access